List of Zorvolex drug patents

Zorvolex is owned by Zyla.

Zorvolex contains Diclofenac.

Zorvolex has a total of 7 drug patents out of which 0 drug patents have expired.

Zorvolex was authorised for market use on 18 October, 2013.

Zorvolex is available in capsule;oral dosage forms.

Zorvolex can be used as treatment of pain.

The generics of Zorvolex are possible to be released after 23 April, 2030.

ZORVOLEX Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186328 ZYLA Formulation of diclofenac
Apr, 2030

(6 years from now)

US9180095 ZYLA Formulation of diclofenac
Apr, 2030

(6 years from now)

US8999387 ZYLA Formulation of diclofenac
Apr, 2030

(6 years from now)

US9173854 ZYLA Formulation of diclofenac
Apr, 2030

(6 years from now)

US9180096 ZYLA Formulation of diclofenac
Apr, 2030

(6 years from now)

US9017721 ZYLA Formulation of diclofenac
Apr, 2030

(6 years from now)

US8679544 ZYLA Formulation of diclofenac
Apr, 2030

(6 years from now)

Do you want to check out ZORVOLEX patents from before 2022?

Drugs and Companies using DICLOFENAC ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Treatment of pain

Dosage: CAPSULE;ORAL

How can I launch a generic of ZORVOLEX before it's patent expiration?
More Information on Dosage

ZORVOLEX family patents

13

United States

5

China

5

Korea, Republic of

4

Australia

3

Hong Kong

3

New Zealand

2

Singapore

2

Japan

2

Mexico

2

European Union

1

Philippines

1

Malaysia

AP

1

AP

1

Denmark

1

Brazil

1

Canada

1

Ukraine

1

Morocco

EA

1

EA

1

Israel

1

South Africa

1

Colombia

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in